Number of eligible patients: CDEC discussed the uncertainty in the number of individuals with reasonably significant to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific specialists consulted by CADTH indicated that some patients who will be labeled as obtaining gentle or moderate ailment can have a critical bleeding https://pieti664nts6.blogspothub.com/profile